Physician profile
Vu Truong
NPI 1134180961
$2,484.57
in general payments reported to CMS, 2019-2025
32 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $232 · 2021: $399 · 2022: $366 · 2023: $492 · 2024: $363 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.28 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $268.20 | 2021-2025 | |
| Exeltis, USA INC. | $235.36 | 2020-2025 | Slynd |
| Pfizer INC. | $160.37 | 2019-2024 | |
| Organon LLC | $129.65 | 2021-2025 | Nexplanon |
| Daiichi Sankyo INC. | $100.90 | 2019-2023 | Injectafer |
| Avion Pharmaceuticals | $86.49 | 2020-2023 | Balcoltra |
| Agile Therapeutics, INC. | $86.17 | 2021-2024 | Twirla |
| Shield Therapeutics INC | $83.12 | 2022-2024 | Accrufer |
| Mylan Pharmaceuticals INC. | $76.02 | 2019-2021 | |
| Hologic Sales and Service, LLC | $74.02 | 2021-2022 | |
| Biogen, INC. | $72.83 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $64.39 | 2019-2025 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $56.35 | 2023-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $50.89 | 2020-2025 | Gardasil 9 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $49.23 | 2019-2025 | Femlyv, Intrarosa |
| Duchesnay USA Incorporated | $42.09 | 2019 | |
| Scynexis, INC. | $39.67 | 2022 | |
| Therapeuticsmd, INC. | $34.17 | 2019-2020 | |
| Astellas Pharma US INC | $33.69 | 2024 | Veozah |
| Innovation Technologies INC | $33.19 | 2024 | Irrisept |
| Ethicon US, LLC | $29.92 | 2021 | |
| Meditrina | $25.76 | 2023 | |
| Davol INC. | $24.80 | 2025 | Arista |
| Minerva Surgical, INC | $24.28 | 2019 | |
| Myovant Sciences INC. | $15.60 | 2022 | |
| Evofem Biosciences, INC. | $14.98 | 2023 | Phexxi |
| Amgen INC. | $13.99 | 2019 | |
| Convatec INC. | $13.06 | 2023 | |
| Lupin INC. | $12.94 | 2020 | |
| Acessa Health INC. | $11.15 | 2020 | |
| Allergan, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.